Varenicline and Lorcaserin for Smoking Cessation and Weight Gain Prevention

Trial Profile

Varenicline and Lorcaserin for Smoking Cessation and Weight Gain Prevention

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 11 Aug 2016

At a glance

  • Drugs Lorcaserin (Primary) ; Varenicline
  • Indications Obesity; Smoking withdrawal
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Aug 2016 Status changed from not yet recruiting to recruiting.
    • 03 May 2016 Planned initiation date changed from 1 Nov 2015 to 1 May 2016.
    • 15 Oct 2015 Study phase changed from I/II to II/III, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top